AVITA Medical Reports First Quarter 2025 Financial Results

About this update from Avita Medical, Inc.

[{"type":"image","alt":"AVITA Medical","displaySize":"","headline":null,"caption":"AVITA Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":96,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ejDr4RdwXqFCjMdbUOz.Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e","width":96,"height":115}},"lazy":false},{"type":"text","content":"VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025.","length":257,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Highlights and Recent Developments","length":63,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross profit margin of 84.7%","length":28,"tagName":"p"}]},{"val":[{"type":"text","content":"In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area wounds","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"On April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed transformation of the commercial organization, shifting from a service-oriented, case-based support structure to a focused, selling-oriented model that enables scalable execution through AVITA Medical’s multi-product platform","length":235,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":626,"olType":false},{"type":"text","content":"“We’ve transformed from a single-product, burn-only company into an integrated, multi-product platform positioned to lead in therapeutic acute wound care,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “With the February rollout of RECELL GO mini and the nationwide launch of Cohealyx on April 1, our portfolio now addresses a U.S. market opportunity that has expan...

More updates from Avita Medical, Inc.